COMPANY
SHENZHEN ALVANTIS PHARMA CO LTD
SHENZHEN ALVANTIS PHARMA CO LTD: API manufacturer, bulk ingredient labeler for Tirzepatide, BPC-157, Bremelanotide, Cagrilintide, CJC-1295, DSIP, GHK-Cu, Ipamorelin, MOTS-c, Retatrutide, Semaglutide, Sermorelin, Tesamorelin, as stated by public registers.
Also written as: Shenzhen Alvantis Pharma Co., Ltd..
API MANUFACTURER
Filed a drug master file with FDA for the active ingredient.
| Tirzepatide | DMF 40668, type II, active, submitted 2024-10-16 Regulator FDA drug master file list |
|---|
BULK INGREDIENT LABELER
Lists the bulk active ingredient with FDA (NDC directory).
| BPC-157 | BPC-157 Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
|---|---|
| BPC-157 | BPC-157 Arginate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| BPC-157 | BPC-157, BULK INGREDIENT Regulator openFDA |
| Bremelanotide | BREMELANOTIDE ACETATE, BULK INGREDIENT Regulator openFDA |
| Cagrilintide | Cagrilintide, BULK INGREDIENT Regulator openFDA |
| CJC-1295 | CJC-1295, BULK INGREDIENT Regulator openFDA |
| DSIP | DSIP, BULK INGREDIENT Regulator openFDA |
| GHK-Cu | Copper Peptide (GHK-Cu), BULK INGREDIENT Regulator openFDA |
| Ipamorelin | Ipamorelin, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| MOTS-c | MOTS-c Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Retatrutide | RETATRUTIDE, BULK INGREDIENT Regulator openFDA |
| Semaglutide | Semaglutide, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Sermorelin | SERMORELIN ACETATE, BULK INGREDIENT Regulator openFDA |
| Tesamorelin | Tesamorelin Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Tesamorelin | TESAMORELIN, BULK INGREDIENT Regulator openFDA |
| Tirzepatide | Tirzepatide, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.